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Insulin pump therapy, alternatively known as 
continuous subcutaneous insulin infusion (CSII), was first 
used in the late 1970s.1 The insulin pump is a portable 
electromechanical device that is worn externally 
on the body. It is filled with short-acting insulin that is 
delivered subcutaneously via an infusion catheter.2 
The infusion site is rotated every two to three days. The 
aim of pump therapy is to replicate the physiological 
delivery of insulin as closely as possible. This necessitates 
a pre-programmed continuous background or basal 
rate, as well as patient-controlled boluses for meals 
and snacks, and for the correction of hyperglycaemia.1
The original pumps were very basic. They were able 
to deliver a fixed basal rate for 24 hours. Boluses were 
delivered manually by the patient in 1 U increments. 
Infusion sets were inserted with an indwelling steel 
cannula, similar to a butterfly needle. These pumps 
were not very popular because of their large size, high 
rates of infusion-site infections, and more frequent 
diabetic ketoacidosis (DKA) than that associated with 
insulin injections.1 These pumps were used in South 
Africa in the 1980s by some diabetologists, but were 
soon abandoned because of poor results.
After the results of the Diabetes Control and 
Complications Trial (DCCT) were published in 1993, 
insulin pumps gained popularity in the USA.1 Insulin 
pump therapy was revived in South Africa in 2002, 
with the introduction of the MiniMed 508® pump. These 
pumps were smaller than the first pumps and were able 
to deliver variable basal rates. Smaller adjustments were 
possible, at 0.1 U increments. The additional ability to 
deliver a temporary basal rate was useful for managing 
illness and exercise. Teflon cannula-tipped infusion sets 
and sensitive high-pressure alarms became available. 
Consequently, rates of infusion-site infections and DKA 
were very low; similar to the DKA rates associated with 
multiple daily injections (MDI) of insulin.2
Insulin pumps have now evolved even further, with 
the addition of even smaller insulin unit increments 
of 0.025 U, features such as bolus calculators that 
help patients to determine their bolus dose based on 
their carbohydrate intake and current blood glucose 
readings, additional meal bolus options to better 
match high-fat content and very low glycaemic index 
meals, and continuous real-time glucose monitoring. 
Two pump brands are available in South Africa: the 
Medtronic Paradigm range of pumps and the Accu-
Chek Spirit Combo pump.
Insulin pumps are very sophisticated devices that 
can assist patients to achieve better blood glucose 
control without the increased risk of hypoglycaemia.1,3-
5-7A meta-analysis of 12 randomised controlled 
trials demonstrated an average HbA1c reduction of 
0.51%.5 Some studies have also shown an increase 
in hypoglycaemia awareness with the use of the 
pumps,8,9 which has also resulted in an improvement in 
quality of life.1,10,11 Despite these advantages, they do 
not work well for all patients. The cost of the pumps and 
pump consumables remains very high. This limits pump 
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Abstract
Insulin pump therapy is an option for intensive insulin therapy in patients with type 1 diabetes who meet the criteria 
described in this article. Pump therapy may assist in the reduction of haemoglobin A1c (HbA1c) and the frequency 
of severe hypoglycaemia. It can also lead to improvements in awareness of hypoglycaemia and quality of life. 
Careful assessment of patients is vital, as pump therapy is an expensive treatment option and can be dangerous 
if used incorrectly. Intensive education of patients who meet the criteria is essential. This will reduce possible risks 
associated with pump therapy. A team approach is needed, consisting of a minimum of a doctor and a diabetes 
educator who are experienced in pump therapy, as well as a registered dietitian who has expertise in carbohydrate 
counting. A psychologist is also a useful member of the team and can help with patient assessment and selection.
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use to wealthy patients or those with medical aids that 
reimburse the cost of the pump therapy. An ethical 
dilemma exists, the resolution of which seeks to balance 
individual patient benefits with the need for society 
and healthcare providers to act as good stewards of 
scarce healthcare resources. The considerable initial 
and ongoing costs, and the defined and measurable 
clinical benefits for a particular patient, must be 
considered on a case-by-case basis. A comparison of 
costs between MDI using insulin analogue pen devices 
and CSII is given in Table I. 
Assessing patients for suitability for pump therapy, as 
well as training and education to initiate pump therapy, 
is very time-consuming for the healthcare provider. A 
typical pump training session lasts a minimum of three 
hours and frequent follow-up is necessary in the first 
few months. In general, patients using pumps require 
more frequent visits to the healthcare provider, on an 
ongoing basis.
Therefore, careful selection of candidates for insulin 
pump therapy is essential. The current South African 
insulin pump therapy guidelines state that pumps 
should be reserved for patients with type 1 diabetes 
who are performing multiple daily injections of insulin, 
and have carried out self-monitoring of blood glucose 
(SMBG) at least four times a day for at least the last 
six months. Patients need to adhere to their diabetes 
treatment plan and be motivated to attain good 
glycaemic control. If, despite these efforts, target 
HbA1c levels have not been achieved, pump therapy 
should be considered,12 for which there should also be 
a specific indication.
The National Institute for Clinical Excellence (NICE) 
guidelines, used in the UK for National Health Service 
funding, describe the following indications:10,13
• Patients with type 1 diabetes, where attempts 
to achieve target HbA1c with MDI results in 
hypoglycaemia that is disabling (i.e. unpredictable, 
causing anxiety and with adverse effects on quality 
of life).
• Patients with type 1 diabetes, where HbA1c remains 
above 8.5% on MDI, despite a high level of care.
• Children under 12 years of age with type 1 diabetes, 
where MDI is impractical or inappropriate.
Quality of life issues that may be improved with insulin 
pump therapy include shift work, frequent travel across 
time zones, a pathological fear of hypoglycaemia, 
needle phobia, impaired exercise capacity and the 
adverse impact of diabetes on family dynamics.10
Insulin pump therapy is a good option for women 
planning pregnancy. Studies suggest that CSII helps to 
lower HbA1c in the preconceptual period, although no 
difference was seen during pregnancy. These studies 
also suggest that CSII may reduce hypoglycaemia 
during pregnancy. Pumps are a safe and effective 
treatment method for patients with type 1 diabetes 
who are pregnant.14-17
The use of insulin pump therapy in children and 
adolescents is also safe and effective. Compared to 
the use of MDI, studies show reductions in HbA1c and 
hypoglycaemia similar to those seen in adults, and 
improvement in quality of life.18-20
When evaluating patients for insulin pump therapy, 
it is vital to discuss the associated advantages and 
disadvantages with them (see Table II), as well as their 
expectations. A patient who believes that the pump 
will monitor their blood glucose and deliver insulin 
accordingly will be very disappointed if the logistics 
of pump therapy have not been explained properly 
when he or she commences using it. 
It is important that the patient is not forced into insulin 
pump therapy. Some patients find it disagreeable to 
be attached to a device all the time, especially young 
girls who wear tight clothing and whose body image is 
important to them. Scarring at infusion sites may also be 
unacceptable. A patient who is not enthusiastic about 
pump therapy constitutes a contraindication for its use.
Table I: Comparison of costs of MDI and CSII
Insulin administration method Monthly cost 
(including VAT)
Multiple daily injections
Insulin aspart disposable pens, based on  
25 U daily
R260
Insulin glargine disposable pens, based on 
25 U daily
R380
Pen needles (10 per month) R32
Total R672
Continuous subcutaneous insulin infusion
Insulin aspart 10 ml vials, based on total daily 
dose of 50 U
R544
Infusion sets (10 per month) R1 187-R1 460*
Reservoirs/cartridges (10 per month) R330-R383*
Initial cost of pump R20 000-R38 000 
(amortised over four years)**
R416-R791
Total R2 477-R3 178
* Prices are given for the cheapest and most expensive choices of these items
** Most patients upgrade their pumps after four years, when the manufacturer’s 
warranty has expired
This cost comparison does not include test strips for the self-monitoring of blood 
glucose. This cost would be similar for both modes of treatment.
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One of the more serious disadvantages of pump 
therapy is the risk of developing DKA if insulin delivery 
is interrupted. This can happen if the patient forgets 
to attach the pump, if the infusion set pulls out or 
becomes blocked, if there is a large quantity of air 
in the system, or if there is pump failure due to a flat 
battery, an empty reservoir or any other technical 
problems. Therefore, regular SMBG, at least four times 
per day, is recommended. This helps with the early 
detection of possible problems. Patients who have 
not demonstrated SMBG four times daily for at least 
the last six months should not be considered for pump 
therapy, as they have not demonstrated the necessary 
commitment to self-care. 
Infection at the infusion sites is another potential risk. 
This can be minimised by regularly changing infusion 
sites (at least every two to three days), as well as by 
maintaining good hygiene practices. The patient who 
does not perform the minimum requirements when 
using MDI is likely to extend the use of infusion sets 
and skip important steps such as hand washing and 
disinfecting the skin with alcohol. Insulin pump therapy 
is not an easier way of treating diabetes. Therefore, it will 
not work well in a patient who is looking for something 
that will control his or her diabetes automatically. 
Pump therapy success is dependent on a patient who 
is motivated, conscientious, and able to learn and 
practise carbohydrate counting,2 and who is willing to 
keep comprehensive diaries of his or her blood glucose 
values, intake of food and insulin administration.
In the South African environment, where funding for 
pump therapy is limited, it is essential that candidates 
are selected who abide by the guidelines. In addition, 
patients who are on pump therapy should be 
continually reviewed to see if they meet the indications 
for pump therapy. Funders are more likely to continue 
to fund pump therapy if the treatment is successful in 
offering clinical benefit.  
Once a potentially successful candidate has been 
selected, he or she will need to learn or review 
carbohydrate counting. Accurate carbohydrate 
counting is essential in order to achieve good results 
with pump therapy. The patient must be referred to 
a registered dietitian who is experienced in teaching 
this skill. Ideally, this should occur at least one month 
before starting pump therapy. The patient will need 
to keep a food, blood glucose and insulin dose diary, 
which should be sent to the dietitian every few days. 
This will help the health professional to gain a more 
accurate idea of the patient’s insulin-to-carbohydrate 
ratio and his or her diurnal variation, and to eliminate 
common mistakes. Gram counting of carbohydrates is 
recommended for better accuracy.
The ideal insulin to use in insulin pump therapy is a rapid-
acting insulin analogue. Several studies have shown 
improved HbA1c and postprandial blood glucose 
control when using rapid-acting analogues, rather 
than regular short-acting insulin in pumps.25-29 A 2011 
study, that compared insulin glulisine, insulin aspart and 
insulin lispro in insulin pump therapy, demonstrated a 
similar performance and no difference in metabolic 
outcome or infusion set occlusion.30
The patient must be advised on which long-acting 
insulin to take the night before or on the morning of 
the start of pump therapy. If the patient is on once-
daily insulin glargine at night, the normal dose should 
be given. It should be taken into account whether or 
not there will be any overlap between the long-acting 
insulin and the pump basal rate on the first day and 
night. The temporary basal rate function must be used 
to reduce the basal rate until the insulin glargine has 
worn off. If the patient is on insulin detemir or neutral 
protamine Hagedorn insulin twice daily, he or she 
should take the normal dose the night before and skip 
the morning dose.
The basic guidelines to calculate the starting pump 
settings are as follows:
• Add up the patient’s current total daily dose (TDD) 
of insulin on injections.
Table II: Advantages and disadvantages of insulin pump 
therapy
Advantages
• More flexible delivery of basal insulin, allowing easier control 
of the “dawn phenomenon”21
• A reduction in severe nocturnal hypoglycaemia
• Improved flexibility in terms of meal size and timing, and 
sleeping late22
• Use of the temporary basal rate allows for easier 
management of exercise and illness22
• Smaller increments of insulin can be delivered accurately
• Less frequent pricks for insulin delivery (once every three 
days, compared to four times a day in the case of MDI)
Disadvantages
• Expensive
• Continuous attachment to a device
• A higher risk of DKA if there are problems with insulin 
delivery23,24
• The risk of infusion site infection and/or contact 
dermatitis23
• Scarring at infusion sites in some individuals
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• Calculate the total daily pump dose (TDPD) by 
reducing the TDD by 20-30% (depending on current 
glycaemic control). A meta-analysis has shown an 
average reduction in insulin requirement of 14% with 
pump therapy, compared to the use of MDI.3 The 
reduction will also reduce the risk of hypoglycaemia, 
which apart from other associated disadvantages, 
will complicate the interpretation of blood glucose 
readings in the first few days.
• Divide the TDPD by 2 to obtain the total basal insulin 
requirement for 24 hours. This can then be divided 
by 24 to obtain a flat hourly rate, or be set according 
to pre-set circadian rhythm patterns.
• The initial insulin-to-carbohydrate ratio can be 
calculated as 500 divided by TDPD, or more 
accurately from the food, blood glucose and insulin 
diaries.
• Insulin sensitivity is calculated as 100 divided by 
TDPD.
For example, in a patient on insulin lispro 6 U three times 
daily and insulin glargine 22 U at night:
• TDD = 40 U
• TDPD = 40 U - 25% = 30 U
• Daily basal dose = 30 U ÷ 2 = 15 U
• Hourly basal rate = daily basal dose (15 U) ÷ 24 = 
0.6 U/hour
• Insulin:carbohydrate ratio = 500 ÷ 30 = 16.6 (round 
up to 17), i.e. 1 U insulin covers 17 g carbohydrate
• Sensitivity = 100 ÷ 30 = 3.3, i.e. 1 U insulin lowers blood 
glucose by 3.3 mmol/l.
Insulin pump training must be carried out by a diabetes 
educator or a doctor who is experienced in pump 
therapy. Typically, an initial start-up training session 
lasts three hours. The patient should be encouraged to 
bring a close relative or friend to the training session. 
The training must be individualised, but initially it is best 
to convey basic pump functions to most patients and 
to teach them the more advanced functions later on. 
Essential knowledge after the first session includes:
• An understanding of pump terminology.
• How to deliver and cancel a bolus dose.
• How to disconnect and reconnect the pump.
• How to change the infusion set.
• The prevention, detection and management of 
hypoglycaemia.
• The management of hyperglycaemia.
• Ketone monitoring and treatment.
In the induction period, SMBG should be carried out 
before and two hours after all meals, as well as at 00h00 
and 03h00. The patient needs to keep a comprehensive 
diary of food intake, carbohydrate count, bolus 
dosages and blood glucose readings. This is essential 
to optimise settings. The patient must have access to a 
24-hour emergency line in the event of any problems. 
Follow-up is required three days after starting on the 
pump so that the patient can change the infusion 
set under supervision. This visit also allows for a review 
of the diabetes diary and the adjustment of settings. 
Further follow-up should be conducted within the next 
month to review data and to teach advanced pump 
functions. Weekly contact with the patient by e-mail 
or fax is essential in the first month until pump settings 
are optimised. Visits to the diabetes educator and 
doctor are recommended at three-monthly intervals. 
The HbA1c level should be checked at each of these 
visits. Regular reviews, in terms of meeting the desired 
outcome for the indication for pump therapy, should 
be carried out. This can be achieved using HbA1c, 
hypoglycaemia awareness questionnaires and quality 
of life questionnaires. If the indications are not being 
met, it is worth considering changing the patient back 
to MDI.10
Some patients do not have improved outcomes with 
insulin pump therapy, even though they may have 
met the criteria for patient selection. In a study that 
examined the influence of psychological factors on 
metabolic control in patients with type 1 diabetes using 
CSII, it was shown that high HbA1c levels correlated with 
a high external locus of control and more depressive 
symptoms.31 Therefore, it is valuable to include a 
psychological assessment when considering a patient 
for pump therapy.
Insulin pump therapy is costly for the patient and time 
consuming for the healthcare provider. It requires 
specialised skills and a team (doctor, educator and 
dietitian) that is experienced in pump therapy.1,10,12 
Twenty-four-hour emergency access is essential for 
patients using pump therapy. Ideally, the latter should 
only be initiated and managed by specialised “insulin 
pump centres”. Careful selection of patients is vital to 
ensure success and to make certain that this limited, 
costly and time-consuming potential resource is not 
wasted.
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